A new clinical trial sponsored by the Kanuni Sultan Suleyman Training and Research Hospital will explore the effectiveness of two commonly used treatments for plantar fasciitis: dextrose prolotherapy and extracorporeal shock wave therapy (ESWT). As of this update, the study is not yet recruiting participants. This trial is part of ongoing efforts to identify optimal treatment strategies for this widely prevalent condition affecting millions globally.
Why is this trial being conducted?
Plantar fasciitis is a common and often debilitating foot condition resulting from inflammation of the plantar fascia. Conventional treatments show varying degrees of success, and many patients experience chronic pain despite intervention. This study addresses the need for evidence-based comparisons between emerging treatments.
This trial will evaluate the effectiveness of dextrose prolotherapy and ESWT, aiming to provide regulatory and clinical stakeholders with robust safety and performance data. The study outcomes could help define best practices for managing plantar fasciitis.
What are the treatment methods under study?
Dextrose prolotherapy
Dextrose prolotherapy involves the injection of a concentrated sugar solution into affected tissues. This method is believed to stimulate healing by promoting local tissue repair processes. It is increasingly used for musculoskeletal disorders, though robust comparative data is limited.
Extracorporeal shock wave therapy (ESWT)
ESWT uses high-energy sound waves to target inflamed tissue. This approach is associated with pain reduction and functional improvements in plantar fasciitis cases. It has gained regulatory approval in many regions for tackling soft tissue conditions.
The trial intends to compare the efficacy, patient outcomes, and safety profiles of these interventions to guide both clinical applications and regulatory considerations.
What are the next steps in the study?
At the current stage, the trial is not yet recruiting participants. Updates on recruitment and study timelines will be provided as they become available. Clinical teams and stakeholders looking to participate or review interim findings are encouraged to monitor ClinicalTrials.gov for real-time updates.
The study link, available here, will provide all necessary details for stakeholders, including inclusion and exclusion criteria, methodology, and anticipated outcomes.
FAQ
- 1. What is plantar fasciitis?
Plantar fasciitis is a condition characterized by pain and inflammation in the plantar fascia, the thick band of tissue connecting the heel bone to the toes. - 2. Who is eligible for the trial?
Eligibility criteria will be detailed on the trial’s official ClinicalTrials.gov page once the recruitment phase begins. - 3. When will results be published?
The trial timeline for participant recruitment and data analysis is not yet available. Stay updated by following the provided trial link.
Conclusion
This trial is expected to provide critical insights into the safety and efficacy of dextrose prolotherapy and ESWT for plantar fasciitis. Clinical, regulatory, and quality teams should monitor the study for data that could inform practice guidelines and market authorizations.
Disclaimer
This article is for informational purposes only and does not constitute legal or medical advice. Always refer to official clinical trial documentation and consult regulatory professionals for compliance matters.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07233395?term=medical+device